Ann: Shareholder Update , page-12

The anticipation of HIV trial results is the main point of interest at the moment but there were some more mundane pieces of information in the news letter that were worth noting.....

The one year follow up to last years HCV trial will be of interest,if BIT225 can prove to make inf/rib more effective by keeping HCV at bay for a longer period this will be significant...

A successful transition to capsule form will also make BIT225 more attractive..

They are manufacturing 10kg of clinical BIT225 with the last batch that was manufactured 6 years ago showing no sign of degradation...


So in short by the end of the year we may have a capsule form drug that is effective against HIV...that makes the current standard of care for HCV perform stronger for longer and wont degrade for 6+years.

Many experimental drugs never reach market because the have failed on these types of hurdles and these types of details can potentially add hundreds of millions of dollars to the value of BIT225.


Michelle Miller must be confident about BIT225 because she appears to be taking steps to ensure BIT225 is a marketable product.GL Holders.